Abstract
The velocity of the COVID-19 pandemic spread and the variable severity of the disease course has forced scientists to search for potential predictors of the disease outcome. We examined various immune parameters including the markers of immune cells exhaustion and activation in 21 patients with COVID-19 disease hospitalised in our hospital during the first wave of the COVID-19 pandemic in Slovakia. The results showed significant progressive lymphopenia and depletion of lymphocyte subsets (CD3+, CD4+, CD8+ and CD19+) in correlation to the disease severity. Clinical recovery was associated with significant increase in CD3+ and CD3+CD4+ T-cells. Most of our patients had eosinopenia on admission, although no significant differences were seen among groups with different disease severity. Non-survivors, when compared to survivors, had significantly increased expression of PD-1 on CD4+ and CD8+ cells, but no significant difference in Tim-3 expression was observed, what suggests possible reversibility of immune paralysis in the most severe group of patients. During recovery, the expression of Tim-3 on both CD3+CD4+ and CD3+CD8+ cells significantly decreased. Moreover, patients with fatal outcome had significantly higher proportion of CD38+CD8+ cells and lower proportion of CD38+HLA-DR+CD8+ cells on admission. Clinical recovery was associated with significant decrease of proportion of CD38+CD8+ cells. The highest AUC values within univariate and multivariate logistic regression were achieved for expression of CD38 on CD8+ cells and expression of PD1 on CD4+ cells alone or combined, what suggests, that these parameters could be used as potential biomarkers of poor outcome. The assessment of immune markers could help in predicting outcome and disease severity in COVID-19 patients. Our observations suggest, that apart from the degree of depletion of total lymphocytes and lymphocytes subsets, increased expression of CD38 on CD3+CD8+ cells alone or combined with increased expression of PD-1 on CD3+CD4+ cells, should be regarded as a risk factor of an unfavourable outcome in COVID-19 patients. Increased expression of PD-1 in the absence of an increased expression of Tim-3 on CD3+CD4+ and CD3+CD8+ cells suggests potential reversibility of ongoing immune paralysis in patients with the most severe course of COVID-19.
Highlights
In 2020, SARS-CoV-2 virus has spread all around the world, causing COVID-19 disease in over 70 million of people worldwide by December 2020
20 patients were selected for the final analysis. They were divided into 4 groups: Group A – 3 patients with asymptomatic, mild to moderate COVID-19, without signs of Patients’ characteristics and comorbidities
Dysregulated immune responses participate in COVID-19 pathogenesis (Quin et al, 2020)
Summary
In 2020, SARS-CoV-2 virus has spread all around the world, causing COVID-19 disease in over 70 million of people worldwide by December 2020. As the worsening of the clinical state, associated with the development of change to: hyperinflammatory syndrome (cytokine storm), may be sudden, from the beginning of this pandemic, clinicians and scientists have been trying to identify potential predictors of the severity of the disease and disease outcome in individual patients. This could help us to identify patients requiring special care: i.e., early ICU admission, intense monitoring, more aggressive and once available, more specific/ targeted therapy. Proven dysregulations of the immunity could justify immune intervention in patients at high risk of poor outcome (Jesenak et al, 2020)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.